World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
31084
World Ranking
17383
National Ranking
8705

Overview

Kathleen N. Moore is affiliated with the University of Oklahoma Health Sciences Center in the United States. Their research primarily focuses on medicine, with a strong emphasis on oncology, reproductive medicine, pulmonary and respiratory medicine, molecular biology, and obstetrics and gynecology.

The body of research conducted by Kathleen N. Moore includes significant topics such as ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, endometrial and cervical cancer treatments, cancer immunotherapy and biomarkers, BRCA gene mutations in cancer, intraperitoneal and appendiceal malignancies, and research on monoclonal and polyclonal antibodies.

Their recent publications include:

  • Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39), 2021, Journal of Clinical Oncology
  • Recent advances and clinical applications of deep learning in medical image analysis, 2022, Medical Image Analysis
  • Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial, 2022, Journal of Clinical Oncology
  • A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45), 2022, Journal of Clinical Oncology
  • The forefront of ovarian cancer therapy: update on PARP inhibitors, 2020, Annals of Oncology

Frequent co-authors collaborating with Kathleen N. Moore include:

  • David M. O'Malley
  • Bradley J. Monk
  • Robert L. Coleman
  • Carol Aghajanian
  • Susana Banerjee

The major publication venues where Kathleen N. Moore's work appears most often include:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • International Journal of Gynecological Cancer
  • Cancer Research

Best Publications

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline ☆

    Alexi A. Wright;Kari Bohlke;Deborah K. Armstrong;Michael A. Bookman

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

    Franz X. Schaub;Varsha Dhankani;Ashton C. Berger;Mihir Trivedi

  • Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

    Panagiotis A. Konstantinopoulos;Steven Waggoner;Gregory A. Vidal;Monica Mita

  • Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

    Mary L. Disis;Mary L. Disis;Matthew H. Taylor;Karen Kelly;J. Thaddeus Beck

  • Antibody-Drug Conjugate-Based Therapeutics: State of the Science.

    Michael J Birrer;Kathleen N Moore;Kathleen N Moore;Ilaria Betella;Richard C Bates

  • Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.

    R. Wendel Naumann;Antoine Hollebecque;Tim Meyer;Michael John Devlin

  • Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?

    Theodore E. Warkentin;Jo-Ann I. Sheppard;Jane C. Moore;Kathleen M. Moore

  • Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

    Joshua D. Campbell;Joshua D. Campbell;Joshua D. Campbell;Christina Yau;Christina Yau;Reanne Bowlby;Yuexin Liu

  • The forefront of ovarian cancer therapy: update on PARP inhibitors.

    M.R. Mirza;R.L. Coleman;A. González-Martín;K.N. Moore

  • Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy

    Nadeem R Abu-Rustum;Mary L Gemignani;Kathleen Moore;Yukio Sonoda

  • Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

    Kathleen N Moore;Kathleen N Moore;Michael Bookman;Jalid Sehouli;Austin Miller

  • The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers

    Dennis S. Chi;Nadeem R. Abu-Rustum;Yukio Sonoda;Joseph Ivy

  • Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

    Kathleen N. Moore;Lainie P. Martin;David M. O’Malley;Ursula A. Matulonis

  • Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

    Pierre-Marie Morice;Alexandra Leary;Charles Dolladille;Basile Chrétien

  • Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    Susana Banerjee;Kathleen N Moore;Nicoletta Colombo;Giovanni Scambia

Frequent Co-Authors

Joan L. Walker
Joan L. Walker University of California, Berkeley
David M. O'Malley
David M. O'Malley The Ohio State University
Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center
Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Bradley J. Monk
Bradley J. Monk University of Arizona
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Robert S. Mannel
Robert S. Mannel University of Oklahoma Health Sciences Center
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in medicine but want to explore alternative healthcare careers or flexible educational routes, there are several respected online degree options. For students prioritizing accessibility, you might consider a nursing school that don't require teas for admission, making entry into the nursing field more straightforward.

Healthcare leadership is another sought-after path. For those aiming for management roles in hospitals or clinics, a health care administration degree online provides the administrative skills needed for these dynamic jobs.

Nursing professionals looking to advance their careers can speed up the process with asn to fnp programs, enabling quicker progression to Family Nurse Practitioner (FNP) roles. Likewise, those passionate about nutrition and health education can earn an online dietitian degree—a flexible way to step into this growing field.

Each of these pathways offers specialized online options for those seeking roles within the diverse healthcare industry beyond traditional medical school.

Best Scientists Citing Kathleen N. Moore

Trending Scientists

Recently Published Articles